Current Edition


Samsung Biologics outlines mRNA ambitions as “Super Plant” speeds toward completion

Samsung Biologics has been on an expansion sprint, with plans to speedily complete a so-called Super Plant already giving way to designs on follow-up facilities …

Continue Reading →

Biogen beefs up in biosimilars—again—with FDA nod for Samsung-partnered Lucentis copycat

Even as Biogen dominates biopharma headlines with its high-profile Aduhelm launch, the company’s budding biosimilar business has been quietly building up—and now, it has another …

Continue Reading →

Samsung plots $205B investment, massive hiring spree to ramp up CDMO, biosimilars and more

With a self-proclaimed “Super Plant” already on the way in South Korea, Samsung Biologics CEO John Rim said in January that the CDMO’s expansion push …

Continue Reading →